Innovating Works

HypoRuLight

Financiado
Hypoxic Tumour Models for Photoactivatable Ruthenium based Chemotherapy
In this Proof-of-Concept project I will show the commercial potential of ruthenium-based photoactivated chemotherapy (PACT) compounds developed in my ERC Starting Grant by demonstrating their efficacy on hypoxic cancer models. Pho... In this Proof-of-Concept project I will show the commercial potential of ruthenium-based photoactivated chemotherapy (PACT) compounds developed in my ERC Starting Grant by demonstrating their efficacy on hypoxic cancer models. Photoactivated chemotherapy is a new class of phototherapy to treat cancer. In principle, PACT looks similar to photodynamic therapy (PDT): light irradiation of the tumour in vivo leads to local activation of the anticancer prodrug, thereby limiting the toxicity of the treatment to the diseased tissue, and thus lowering side effects for the patient. However, the mechanisms of PACT and PDT are very different: in PDT the light-absorbing prodrug requires molecular oxygen to kill the cancer cells, whereas in PACT oxygen is not involved in prodrug activation. As a consequence, PACT agents should be able to treat hypoxic tumours, which are characterized by low oxygen concentrations and high resistance to PDT and other existing therapies. In this project the efficacy of a selection of Ru-based PACT compounds will be tested in hypoxic cancer models and compared to their efficacy in normoxic conditions. In parallel I will develop, in collaboration with my network of collaborators from the clinics, business analysts, and patent attorney, a plan for (pre) clinical development of PACT compounds. ver más
31/03/2019
150K€
Duración del proyecto: 18 meses Fecha Inicio: 2017-09-30
Fecha Fin: 2019-03-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-03-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2017-PoC: ERC-Proof of Concept
Cerrada hace 7 años
Presupuesto El presupuesto total del proyecto asciende a 150K€
Líder del proyecto
UNIVERSITEIT LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5